Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt
the severe inflammatory response at the alveolar level, delaying or reversing the path
towards oxygen desaturation, ARDS, requirement for supplemental oxygenation, artificial
ventilation or death in patients with COVID-19 on supplemental oxygen.
* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The
World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee
revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN
) Council for use in the U.S. and is pending formal adoption by the INN for international
use.